Clinical implications of an accurate problem list on heart failure treatment
- 52 Downloads
CONTEXT: The premise of the problem-oriented medical record is that an accurately defined problem list will directly result in more thorough and efficient patient care. However, little empirical evidence exists demonstrating improved patient outcomes as a result of an adequately structured problem list.
OBJECTIVE: To determine the impact of problem list documentation of heart failure on the likelihood that evidence-based pharmacotherapy has been prescribed.
DESIGN: Cross-sectional study.
SETTING: Community-based primary care clinics in Portland, Oregon.
SUBJECTS: Active patients in the network with a left ventricular ejection fraction of 40% or less, with and without heart failure, in their structured problem list.
MAIN OUTCOME MEASURES: The proportion of patients prescribed medications with known benefits for systolic dysfunction.
RESULTS: In this group of patients with known systolic dysfunction, the likelihood of therapy with either an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker was higher in patients who had heart failure listed on their problem list compared to patients who did not (92.2% vs 76.7%; P<.05). This association remained after statistical adjustment for age, gender, and ejection fraction. Patients with accurate problem list entries were also more likely to receive digoxin (61.1% vs 36.7%; P=.001) and spironolactone (26.7% vs 13.3% P=.025). There were no differences in the use of beta-blockers between the 2 groups.
CONCLUSION: Accurate documentation of heart failure on the problem list of patients with known systolic dysfunction is associated with a significant increase in the likelihood of being prescribed medications with known clinical benefit.
Key wordsproblem-oriented medical records heart failure quality indicators drug therapy
Unable to display preview. Download preview PDF.
- 5.Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.Google Scholar
- 7.Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001;38:2101–13.PubMedCrossRefGoogle Scholar
- 11.Univasc [package insert]. Milwaukee, WI: Schwarz Pharma; 2001.Google Scholar
- 12.Lotensin [package insert]. East Hanover, NJ: Novartis; 2002.Google Scholar
- 13.Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRefGoogle Scholar
- 15.Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley-Interscience; 2000.Google Scholar
- 17.The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–46.Google Scholar
- 19.Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, MA: Little, Brown and Company; 1987.Google Scholar